Athersys Inc
OTC:ATHXQ
Athersys Inc
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. The company is headquartered in Cleveland, Ohio and currently employs 104 full-time employees. The company went IPO on 2007-04-23. The company is engaged in the discovery and development of therapeutic product candidates. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. The MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells may alternatively be obtained from other tissue sources. The company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MASTERS-2. The company is enrolling a pivotal Phase II/III clinical trial evaluating MultiStem cell therapy in COVID-19 induced and other pathogen-induced acute respiratory distress syndrome (ARDS) patients.
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. The company is headquartered in Cleveland, Ohio and currently employs 104 full-time employees. The company went IPO on 2007-04-23. The company is engaged in the discovery and development of therapeutic product candidates. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. The MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells may alternatively be obtained from other tissue sources. The company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MASTERS-2. The company is enrolling a pivotal Phase II/III clinical trial evaluating MultiStem cell therapy in COVID-19 induced and other pathogen-induced acute respiratory distress syndrome (ARDS) patients.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
